Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.

被引：0
|
作者：
McArthur, H. L. [1 ]
Rugo, H. [2 ]
Nulsen, B. [1 ]
Traina, T. [1 ]
Patil, S. [1 ]
Zhou, Q. [1 ]
Steingart, R. [1 ]
Dang, C. [1 ]
Park, J. [2 ]
Moasser, M. [2 ]
Melisko, M. [2 ]
Sugarman, S. [1 ]
Norton, L. [1 ]
Hudis, C. [1 ]
Dickler, M. N. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：281S / 282S
页数：2
相关论文
共 50 条
  • [1] Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety
    Dickler, M. N.
    Traina, T.
    Panageas, K.
    Steingart, R.
    Dang, C.
    Fornier, M.
    Sugarman, S.
    Norton, L.
    Hudis, C.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer
    McArthur, H. L.
    Rugo, H.
    Paulson, M.
    Rourke, M.
    Traina, T.
    Panageas, K.
    Steingart, R.
    Dang, C.
    Fornier, M.
    Park, J.
    Moasser, M.
    Melisko, M.
    Sugarman, S.
    Norton, L.
    Hudis, C. A.
    Dickler, M. N.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S147 - S148
  • [3] Troponins Do Not Predict Cardiotoxicity in a Pilot Study of Adjuvant Bevacizumab (B) Plus Dose-Dense Doxorubicin/Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel (nab-P).
    McArthur, H. L.
    Rugo, H.
    Nulsen, B.
    Patil, S.
    Steingart, R.
    Melisko, M.
    Grothusen, J.
    Traina, T.
    Norton, L.
    Hudis, C. A.
    Dickler, M. N.
    CANCER RESEARCH, 2009, 69 (24) : 675S - 675S
  • [4] Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
    Pippen, John
    Paul, Devchand
    Vukelja, Svetislava
    Clawson, Alicia
    Iglesias, Jose
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (03) : 825 - 831
  • [5] Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
    John Pippen
    Devchand Paul
    Svetislava Vukelja
    Alicia Clawson
    Jose Iglesias
    Breast Cancer Research and Treatment, 2011, 130 : 825 - 831
  • [6] A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer
    McArthur, Heather L.
    Rugo, Hope
    Nulsen, Benjamin
    Hawks, Laura
    Grothusen, Jill
    Melisko, Michelle
    Moasser, Mark
    Paulson, Matthew
    Traina, Tiffany
    Patil, Sujata
    Zhou, Qin
    Steingart, Richard
    Dang, Chau
    Morrow, Monica
    Cordeiro, Peter
    Fornier, Monica
    Park, John
    Seidman, Andrew
    Lake, Diana
    Gilewski, Theresa
    Theodoulou, Maria
    Modi, Shanu
    D'Andrea, Gabriella
    Sklarin, Nancy
    Robson, Mark
    Moynahan, Mary Ellen
    Sugarman, Steven
    Sealey, Jane E.
    Laragh, John H.
    Merali, Carmen
    Norton, Larry
    Hudis, Clifford A.
    Dickler, Maura N.
    CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3398 - 3407
  • [7] Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC)
    Sierecki, M. R.
    Rugo, H. S.
    McArthur, H. L.
    Traina, T. A.
    Paulson, M.
    Rourke, M.
    Norton, L.
    Seidman, A. D.
    Hudis, C. A.
    Dickler, M. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer.
    Snider, J. N.
    Allen, J. W.
    Young, R.
    Schwartzberg, L.
    Javed, Y.
    Jahanzeb, M.
    Sachdev, J. C.
    CANCER RESEARCH, 2012, 72
  • [9] Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.
    Khasraw, Mustafa
    Mukaro, Violet Rudo
    West, Linda
    White, Karen
    Rippy, Elisabeth
    Brandt, Conrad
    Tobler, Robert
    Murphy, Caitlin Clare
    Collins, Ian M.
    Baron-Hay, Sally E.
    Ashley, David M.
    Patil, Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study
    Burstein, H. J.
    Mayer, E. L.
    Peppercorn, J.
    Parker, L. M.
    Hannagan, K.
    Moy, B.
    Younger, J.
    Schapira, L.
    Wulf, G.
    Gelman, R.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345